Kidney fibrosis is a direct consequence of the kidney's limited capacity to regenerate after injury. Renal scarring results in a progressive loss of renal function, ultimately leading to end-stage renal failure and a requirement for dialysis or kidney transplantation.

Chronic kidney disease (CKD) is a condition characterized by a gradual loss of kidney function over time and affects 7.2% of the general population. Early stages of CKD usually do not show clear symptoms, which is translated into a high rate of underdiagnosed and untreated CKD patients, as well as in an economic burden.

UNMET NEED

Novel patient-friendly methods of kidney function measurement with high levels of precision and reproducibility are urgently needed to ensure early diagnosis and more frequent and reliable monitoring.

The team has discovered that increased levels of Vitronectin in urine extracellular vesicles could indicate a higher degree of renal fibrosis, without the need of renal biopsy, thus allowing a frequent, non-invasive monitoring of patients.

THE ASSET

Mechanism of action: IVD, Biomarkers test Vitronectin
Potential indications:
Identification of fibrosis grade
Monitorization of renal fibrosis

IP Protection: PCT/EP2020/087290

Business model:

MAIN STREAM REVENUES//BUSINESS MODEL

Lateral flow Diagnostic Kit & Reader device
 ✓ Lateral Flow Stand-Alone IVD
   As there are no other tests on the market
   Including both clinical and research use
   Additional revenue related to a Reader
 ✓ Research Use Only at the early stages
 ✓ Companion Diagnostics on the under development drugs for kidney fibrosis
 ✓ Screening and monitorization of kidney fibrosis

ELISA Diagnostic Kit
 ✓ ELISA Stand-Alone IVD
 ✓ Research Use Only
 ✓ Stratification of fibrosis grade

OPPORTUNITY

Spin-off generation
Part-time CEO

CONTACT

innovation@igtp.cat
Innovation & Business Development Unit

ENTREPRENEUR

feborras@igtp.cat
Francesc Enric Borràs
IVECAT Group